Avalo Therapeutics (NASDAQ:AVTX) Receives "Buy" Rating from BTIG Research

Key Points

• BTIG Research reiterated a "Buy" rating on Avalo with a $40 price target, implying roughly a 192.8% upside from the current price.
• The stock has a consensus rating of "Moderate Buy" with a consensus price target of $44.83; shares opened at $13.66, have a 1‑year range of $3.39–$20.72 and a market cap of about $311.3 million.
• Insiders have sold a total of 46,100 shares (~$764,724) in the last 90 days while institutional investors own 87.06% of the company, with several hedge funds recently increasing positions.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report)'s stock had its "buy" rating restated by equities research analysts at BTIG Research in a research note issued to investors on Monday,Benzinga reports. They currently have a $40.00 target price on the stock. BTIG Research's price objective would indicate a potential upside of 192.83% from the company's current price.

A number of other research analysts also recently commented on AVTX. Wall Street Zen upgraded Avalo Therapeutics from a "strong sell" rating to a "hold" rating in a report on Sunday, March 29th. Mizuho upgraded Avalo Therapeutics to a "strong-buy" rating in a report on Thursday, December 18th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Avalo Therapeutics in a report on Wednesday. Citizens Jmp began coverage on Avalo Therapeutics in a report on Monday, April 6th. They issued an "outperform" rating and a $52.00 price objective on the stock. Finally, Guggenheim began coverage on Avalo Therapeutics in a report on Monday, February 2nd. They issued a "buy" rating and a $50.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Avalo Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.83.

Avalo Therapeutics Price Performance

Shares of NASDAQ AVTX opened at $13.66 on Monday. The stock's 50-day moving average is $15.49 and its two-hundred day moving average is $16.15. Avalo Therapeutics has a 1-year low of $3.39 and a 1-year high of $20.72. The company has a market cap of $311.28 million, a price-to-earnings ratio of -2.38 and a beta of 0.93.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last issued its quarterly earnings results on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($1.54) by $1.17. The company had revenue of $0.06 million for the quarter, compared to analysts' expectations of ($0.21) million. Equities research analysts anticipate that Avalo Therapeutics will post -19.07 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Christopher Ryan Sullivan sold 7,980 shares of the firm's stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $17.15, for a total transaction of $136,857.00. Following the transaction, the chief financial officer owned 17,338 shares in the company, valued at $297,346.70. This trade represents a 31.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mittie Doyle sold 25,492 shares of the firm's stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $16.15, for a total value of $411,695.80. Following the transaction, the insider owned 3,622 shares in the company, valued at $58,495.30. This represents a 87.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 46,100 shares of company stock worth $764,724 in the last 90 days. 3.03% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP purchased a new position in Avalo Therapeutics during the 4th quarter worth approximately $1,150,000. XTX Topco Ltd grew its stake in Avalo Therapeutics by 190.0% during the 4th quarter. XTX Topco Ltd now owns 40,458 shares of the company's stock worth $735,000 after buying an additional 26,508 shares during the last quarter. Squadron Capital Management LLC purchased a new position in Avalo Therapeutics during the 4th quarter worth approximately $2,361,000. SummitTX Capital L.P. purchased a new position in Avalo Therapeutics during the 4th quarter worth approximately $3,557,000. Finally, Millennium Management LLC grew its stake in Avalo Therapeutics by 380.2% during the 4th quarter. Millennium Management LLC now owns 659,979 shares of the company's stock worth $11,985,000 after buying an additional 522,548 shares during the last quarter. Hedge funds and other institutional investors own 87.06% of the company's stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.